(Q44247986)

1 December 2017

title

Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome (English)

1 reference

1 December 2017

0 references

visceral leishmaniasis

1 reference

2

1 reference

1 December 2017

Rachel ter Horst

1

1 reference

1 December 2017

Koert Ritmeijer

series ordinal

3

1 reference

1 December 2017

Adey Bogale

series ordinal

4

1 reference

1 December 2017

Robert N Davidson

series ordinal

5

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

Clinical Infectious Diseases

1 December 2017

published in

1 reference

1 December 2017

volume

46

1 reference

1 December 2017

issue

11

1 reference

1 December 2017

page(s)

1702-1709

1 reference

The increase in risk factors for leishmaniasis worldwide

1 December 2017

cites work

1 reference

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

21 January 2018

1 reference

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study

21 January 2018

1 reference

Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts

21 January 2018

1 reference

Leishmania/HIV co-infections: epidemiology in Europe.

21 January 2018

1 reference

Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region

21 January 2018

1 reference

HIV-associated visceral leishmaniasis

21 January 2018

1 reference

Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections.

21 January 2018

1 reference

The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV.

21 January 2018

1 reference

Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients

21 January 2018

1 reference

Leishmania/HIV co-infection in Brazil: an appraisal

21 January 2018

1 reference

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

21 January 2018

1 reference

Visceral leishmaniasis and HIV in Tigray, Ethiopia

21 January 2018

1 reference

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

21 January 2018

1 reference

Emerging Leishmania/HIV co-infection in Africa.

21 January 2018

1 reference

Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

21 January 2018

1 reference

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/587899

1 reference

1 December 2017

1 reference